Grace Therapeutics, Inc.
GRCENASDAQHealthcare● Active
$2.37
+$0.07(+2.83%)
Market Cap$36596010
P/E Ratio—
52W High$5.18
52W Low$1.79
Grace Therapeutics, Inc. (GRCE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GRCE · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 12, 2026EPS Actual
-$0.14
Est. -$0.09 · -55.6%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 12, 2026
After Market Close
▼ Miss EPS
GRCE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Jun 22, 2026 | -$0.24 | — | — | — | $0.00B | — |
| ▼ Q1 FY2026 | Feb 12, 2026 | -$0.09 | -$0.14 | -55.6% | — | — | — |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.12 | -$0.15 | -25.0% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.22 | -$0.21 | +4.5% | — | — | — |
| ▼ Q2 FY2025 | Jun 23, 2025 | -$0.20 | -$0.21 | -5.0% | — | — | — |
| ▼ Q1 FY2025 | Feb 13, 2025 | -$0.24 | -$0.26 | -8.3% | — | — | — |
| — Q4 FY2024 | Nov 13, 2024 | -$0.33 | -$0.33 | +0.0% | — | — | — |
| ▲ Q3 FY2024 | Aug 9, 2024 | -$0.28 | -$0.24 | +14.3% | — | — | — |
Q2 FY2026
Jun 22, 2026
EPS Actual
—
EPS Est.
-$0.24
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 12, 2026Miss
EPS Actual
-$0.14
EPS Est.
-$0.09
EPS Surpr.
-55.6%
Revenue
—
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.15
EPS Est.
-$0.12
EPS Surpr.
-25.0%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.22
EPS Surpr.
+4.5%
Revenue
—
Q2 FY2025
Jun 23, 2025Miss
EPS Actual
-$0.21
EPS Est.
-$0.20
EPS Surpr.
-5.0%
Revenue
—
Q1 FY2025
Feb 13, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.24
EPS Surpr.
-8.3%
Revenue
—
Q4 FY2024
Nov 13, 2024
EPS Actual
-$0.33
EPS Est.
-$0.33
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2024
Aug 9, 2024Beat
EPS Actual
-$0.24
EPS Est.
-$0.28
EPS Surpr.
+14.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q4 FY2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q3 FY2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q2 FY2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q1 FY2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q4 FY2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 12, 2026 | -55.6% | $3.59 | $3.53 | -1.67% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -25.0% | $3.03 | $3.10 | +2.31% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +4.5% | $3.10 | $3.21 | +3.55% |
| ▼ Q2 FY2025 | Jun 23, 2025 | -5.0% | $3.00 | $2.93 | -2.33% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -8.3% | $3.48 | $3.48 | +0.00% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +0.0% | $3.19 | $3.05 | -4.39% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +14.3% | No price data | $3.01 | — |
| ▲ Q2 FY2024 | Jun 21, 2024 | +48.6% | No price data | $3.01 | — |
Q1 FY2026-1.67%
Report Date
Feb 12, 2026
EPS Beat/Miss
-55.6%
Price Before
$3.59
Price After
$3.53
Q4 FY2025+2.31%
Report Date
Nov 13, 2025
EPS Beat/Miss
-25.0%
Price Before
$3.03
Price After
$3.10
Q3 FY2025+3.55%
Report Date
Aug 12, 2025
EPS Beat/Miss
+4.5%
Price Before
$3.10
Price After
$3.21
Q2 FY2025-2.33%
Report Date
Jun 23, 2025
EPS Beat/Miss
-5.0%
Price Before
$3.00
Price After
$2.93
Q1 FY2025+0.00%
Report Date
Feb 13, 2025
EPS Beat/Miss
-8.3%
Price Before
$3.48
Price After
$3.48
Q4 FY2024-4.39%
Report Date
Nov 13, 2024
EPS Beat/Miss
+0.0%
Price Before
$3.19
Price After
$3.05
Q3 FY2024—
Report Date
Aug 9, 2024
EPS Beat/Miss
+14.3%
Price Before
—
Price After
$3.01
Q2 FY2024—
Report Date
Jun 21, 2024
EPS Beat/Miss
+48.6%
Price Before
—
Price After
$3.01
Avg Beat Reaction-0.42%
Avg Miss Reaction-0.42%
Beat Rate4 / 8 quarters
Largest Move-4.39% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GRCE ends December
Grace Therapeutics, Inc. (GRCE) most recently reported earnings on February 12, 2026 for Q1 FY2026, posting EPS of $-0.14 — missing the analyst consensus of $-0.09 by -55.6%. The next GRCE earnings date is expected around September 1, 2026.
Each quarter, investors track GRCE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GRCE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GRCE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GRCE earnings · 5 questionsGrace Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. GRCE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GRCE historically reports after market close (AMC).
GRCE earnings datewhen is GRCE earningsGRCE next earnings datewhen does GRCE report earningsGRCE earnings calendar
▸ Source: FMP · Grace Therapeutics, Inc. SEC filings · US GAAP · Grace Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026